Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Cerebras Systems | SanDisk | Pfizer | |
|---|---|---|---|
| Moat rating | narrow One-of-a-kind silicon sold to very few buyers: the IPO prospectus discloses G42 at 24.0% of 2025 revenue (85.0% in 2024), MBZUAI at 62.0% of 2025 revenue, and a December 2025 MRA with OpenAI representing 'a substantial portion of our projected revenues over the next several years' — against a competitive field the same document names as NVIDIA, AMD, Intel, hyperscaler accelerators and the major clouds. | narrow Narrow rather than wide: the FY2025 10-K Competition section opens 'Our industry is highly competitive' and names five vertically integrated flash rivals (Kioxia, Micron, Samsung, SK Hynix, Yangtze Memory), while Item 1A concedes SanDisk's products 'are designed to be largely interchangeable with competitors' products' in a market 'often subject to declining average selling prices'. It is not 'none', because the same filing discloses a genuinely durable consumer franchise and roughly 7,900 granted patents. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip Wafer-scale integration is the moat's substance: the prospectus contrasts the WSE-3's 4 trillion transistors on 46,225 mm² of silicon with NVIDIA's B200 at 208 billion on roughly 1,600 mm² — a commercial chip category with one occupant. | intangibles ip The only hard-to-replicate assets the filing actually claims are intangible: it reports 'a strong position in the Consumer end market' with 'significant consumer brands and franchises globally, with valuable patent portfolios containing approximately 7,900 granted patents and approximately 3,200 pending patent applications worldwide', and adds that non-patented IP, 'particularly some of our process technology, is an important factor in our success'. Cost-scale is the wrong label because the manufacturing scale sits in Flash Ventures, a 49.9%-owned JV co-owned with Kioxia, not in a proprietary fab base. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | clear leader Scoped to the category the record supports: wafer-scale integration has no other commercial occupant per the prospectus's own comparison, and the Q2 release claims — attributed, via AMD and AWS partnerships — leadership in disaggregated inference, a technique the prospectus defines. | at parity At parity, not ahead: the 10-K Competition section positions SanDisk against vertically integrated suppliers Kioxia, Micron, Samsung, SK Hynix and Yangtze Memory, and Item 1A concedes its products are 'designed to be largely interchangeable with competitors' products'. Its explicit leadership claims are brand- and consumer-scoped ('industry leading consumer brand awareness and global retail distribution presence'), not technology- or share-scoped. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate The CFO states Q2 'significantly improved core gross and operating margins compared to a year ago' — improving, from a base where three named customers hold most of the revenue and the leverage that comes with it. | weak A price taker. The 10-K describes an industry 'often subject to declining average selling prices' and warns that competitors 'may utilize pricing strategies, including offering products at prices at or below cost, that we may be unable to competitively match'. Gross margin swung from 7.1% (FY2023) to 16.1% (FY2024) to 30.1% (FY2025) on the cycle rather than on sustained pricing, and FY2025 Consumer ASP per gigabyte still fell 7% 'due to pricing pressure'. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Cerebras bet that AI compute should be one enormous chip rather than many small ones — 'quantities of compute and memory never before assembled on a single commercial chip,' avoiding 'the latency and the power-draw induced by the traditional approach,' in the prospectus's words — and is converting that bet into an inference cloud: Q2 2026 cloud revenue grew 281% with 600 MW of data center capacity under contract and $25.4 billion of remaining performance obligations. The concentration that funded the bet is the risk that remains: two related-party Gulf customers were 86% of 2025 revenue between them, with the OpenAI MRA now layered on top. | SanDisk sells largely interchangeable NAND product into a five-rival commodity market, so its defensible edge is narrow and concentrated in intangibles: the SanDisk consumer brand and retail distribution (Consumer was $2,268M of $7,355M FY2025 revenue) plus roughly 7,900 granted patents. It owns no flash fab of its own; the 10-K says substantially all of its flash memory wafers come from Flash Ventures, its 49.9% JV with Kioxia, whose fixed costs it must fund at about half regardless of the output it takes. That structure caps both the moat and the downside cushion: gross margin ran 7.1% in FY2023, 16.1% in FY2024 and 30.1% in FY2025 as the flash cycle turned. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Layer-4 wafer-scale accelerators plus an inference cloud — hardware vendor and specialized cloud in one node. | Merchant NAND/SSD supplier with no wholly owned fab: substantially all flash wafers come from Flash Ventures, its 49.9% JV with Kioxia across seven Japanese fabs, with an eighth due to start in calendar 2025. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.20 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |